Bullous pemphigoid (BP) is an autoimmune disorder that mainly affects older adults. The condition causes your immune system to attack proteins that hold the layers of your skin together. This damages ...

What Is Dupixent, and Why Does It Matter? Dupixent (dupilumab) is a prescription medicine for treating various allergic conditions and is given as a shot under the skin. The FDA has now approved ...

The FDA approval of the biologic drug Dupixent for allergic fungal rhinosinusitis may help patients living with this challenging condition and help them avoid repeat surgeries. The U.S. Food and Drug ...

Dupixent (dupilumab) is a prescription drug that works to treat certain inflammatory conditions. It does so by reducing inflammation signals in your immune system. Your response to this drug may vary ...

The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for treating adults with bullous pemphigoid (BP), a chronic and debilitating skin disease primarily affecting the elderly ...

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery ...

Dupixent (dupilumab), a drug already used to treat atopic dermatitis and asthma, became the first biologic approved for chronic obstructive pulmonary disease (COPD) last fall. Most COPD treatments ...

The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for treating adults and adolescents aged 12 and older with chronic spontaneous urticaria (CSU) who continue to experience ...

Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions First and only therapy to specifically target the ...

Regeneron Pharmaceuticals and Sanofi said a key European regulatory committee has recommended expanded approval of their blockbuster anti-inflammatory drug Dupixent for younger patients with the ...

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo ...